NCT01740388终止3 期
A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 136
- 试验地点
- 1
- 主要终点
- Clinical Resolution
研究概览
简要总结
To evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension, 0.6% (Besifloxacin) administered BID for 3 days compared to vehicle in the treatment of bacterial conjunctivitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 1 Year 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a clinical diagnosis of acute bacterial conjunctivitis and exhibit mucopurulent/purulent conjunctival discharge (crusty or sticky eyelids) and redness in at least 1 eye. A minimum score of 1 should be present for both discharge and for bulbar conjunctival injection.
- •Have monocular pin-holed Snellen visual acuity (VA) equal to or better than 20/200 in both eyes. Age appropriate VA testing will be performed. Every effort should be made to obtain a VA measurement in children. If VA is unobtainable in children, it is at the Investigator's discretion to include the subject in the study.
- •Be willing to discontinue contact lens wear for the duration of the study.
排除标准
- •Have a severe/serious ocular condition or history/presence of chronic generalized systemic disease that the Investigator feels might increase the risk to the subject or confound the result(s) of the study.
- •Have a known hypersensitivity or contraindications to besifloxacin, fluoroquinolones, or any of the ingredients in the study drugs.
- •Be expected to require treatment with systemic or ocular (either eye) nonsteroidal anti-inflammatory drugs (NSAIDs), antihistamines, or corticosteroids during the study or have used any of these medications within 2 days prior to study start.
- •Be expected to require concurrent ocular therapy in either eye with any ophthalmic solutions (unless specified below), including tear substitutes, during the study or have used any ophthalmic solutions within 2 hours prior to study start. Be expected to require concurrent ocular therapy (either eye) with mast cell stabilizers or decongestants during the study or have used any of the above within 2 days prior to study start.
- •Be expected to require concurrent systemic or ocular therapy with immunosuppressants (eg, Restasis) during the study or have used systemic or ocular immunosuppressants within 30 days prior to study start.
- •Be expected to require treatment with systemic or ocular (either eye) antibacterials (other than study drug) during the study or have used any systemic or ocular antibacterial within 3 days prior to study start.
- •Be likely to require antimicrobial therapy for conditions such as respiratory tract infection, urinary tract infection, skin/soft tissue infection, or otitis media during the study.
- •Have had ocular surgery (including laser surgery) in either eye within 6 weeks prior to entry into this study.
- •Have suspected viral or allergic conjunctivitis or any other disease conditions that could interfere with the efficacy and safety evaluations of the study medication.
- •Have suspected iritis
- •Have a history of recurrent corneal erosion syndrome, either idiopathic or secondary to previous corneal trauma or dry eye syndrome.
- •Have any active ulcerative keratitis, specifically any epithelial loss greater than punctate keratitis.
- •Be immune compromised.
研究组 & 干预措施
Besifloxacin
Experimental
besifloxacin ophthalmic suspension 0.6% administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
干预措施: Besifloxacin (Drug)
Vehicle
Placebo Comparator
vehicle of besifloxacin ophthalmic suspension administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
干预措施: Vehicle (Drug)
结局指标
主要结局
Clinical Resolution
时间窗: Visit 2 (Day 4 or 5)
Absence of both conjunctival discharge and bulbar conjunctival injection, after 3 days of treatment with besifloxacin ophthalmic suspension 0.6%
Microbial Eradication
时间窗: Visit 2 (Day 4 or 5)
Absence of all accepted ocular bacterial species that were present at or above threshold at baseline, after 3 days of treatment with besifloxacin ophthalmic suspension 0.6%
次要结局
- Clinical Resolution(Visit 3 (Day 6, 7, or 8))
- Microbial Eradication(Visit 3 (Day 6, 7, or 8))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial ConjunctivitisBacterial ConjunctivitisNCT00972777Bausch & Lomb Incorporated474
已完成
1 期
Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract SurgeryMicrobial DiseaseCataract SenileNCT04542759Instituto de Oftalmología Fundación Conde de Valenciana60
已完成
不适用
Besifloxacin in Bacterial KeratitisBacterial KeratitisNCT02497365McGill University Health Centre/Research Institute of the McGill University Health Centre32
已完成
3 期
Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to VehicleBacterial ConjunctivitisNCT01175590Bausch & Lomb Incorporated518
已完成
1 期
Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in ChildrenCongenital Nasolacrimal Duct ObstructionNCT01431170Rutgers, The State University of New Jersey24